*G. Sridhar Prasad, PhD* *Chief Scientific Officer* *Plex Pharmaceuticals & Collidion Inc.* *6330 Nancy Ridge Drive, S105**San Diego, CA 92121*
*Ph: 858-587-8800 (o)** 858-733-0858 (M)* *spra...@plexpharma.com <spra...@plexpharma.com>* *www.plexpharma.com <http://www.plexpharma.com>* *www.collidion.com <http://www.plexpharma.com>* The contents of this e-mail message, including any attachments, are intended solely for the use of the person or entity to whom the e-mail was addressed. It contains information that may be protected by the consultant-client privilege, work-product doctrine, or other privileges, and may be restricted from disclosure by applicable state and federal law. If you are not the intended recipient of this message, be advised that any dissemination, distribution, or use of the contents of this message is strictly prohibited. If you received this e-mail message in error, please e-mail i...@plexpharma.com and contact the sender by reply e-mail. Please also permanently delete all copies of the original e-mail and any attached documentation. Thank you. ######################################################################## To unsubscribe from the CCP4BB list, click the following link: https://www.jiscmail.ac.uk/cgi-bin/WA-JISC.exe?SUBED1=CCP4BB&A=1 This message was issued to members of www.jiscmail.ac.uk/CCP4BB, a mailing list hosted by www.jiscmail.ac.uk, terms & conditions are available at https://www.jiscmail.ac.uk/policyandsecurity/
